Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.36 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | TACR2 | P21452 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 7/20 | 0.34 |
| ▸ | CTSB | P07858 | 7/20 | 0.34 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20341767 | 0.90 | ABL1 (0.37) | PDE7BRAB9A | |
| SCHEMBL18615930 | 0.86 | CTSL (0.46) | CTSSCTSKTACR2CTSLCTSB | |
| SCHEMBL20341766 | 0.84 | TACR2 (0.36) | CTSSCTSKTACR2CTSLCTSB | |
| SCHEMBL18615884 | 0.81 | CTSL (0.44) | CTSSCTSKTACR2CTSLCTSB | |
| SCHEMBL18616483 | 0.81 | CTSL (0.44) | CTSSCTSKTACR2CTSLCTSB | |
| SCHEMBL23810294 | 0.79 | TACR2 (0.35) | CTSSCTSKTACR2CTSLCTSB | |
| SCHEMBL18616609 | 0.79 | CTSL (0.45) | CTSSCTSKTACR2CTSLCTSB | |
| SCHEMBL18615883 | 0.79 | CTSL (0.45) | CTSSCTSKTACR2CTSLCTSB | |
| SCHEMBL23810234 | 0.79 | CTSL (0.42) | CTSSCTSKTACR2CTSLCTSB | |
| SCHEMBL20341809 | 0.77 | PDE7B (0.37) | PDE7BRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017036357-A1 | CATHEPSIN K INHIBITOR AND APPLICATION THEREOF | 广东东阳光药业有限公司 | 2017-03-09 | — | — | WO | disclosed |